Department of Cardiology, Medical University of Bialystok, ul. M. Sklodowskiej-Curie 24a, 15-276 Bialystok, Poland.
Int J Cardiol. 2011 Apr 1;148(1):70-5. doi: 10.1016/j.ijcard.2009.10.026. Epub 2009 Nov 18.
GRACE, TIMI, Zwolle, and CADILLAC are risk scores designed for predicting short-term outcome after acute coronary syndromes. The aim of our study was to test their utility for a prognosis of 5-year survival in a "real-life" population of patients with ST-elevation myocardial infarction (STEMI) treated with primary percutaneous coronary interventions (pPCI).
Our registry consisted of consecutive patients with STEMI treated with pPCI. Five-year follow-up was performed with all-cause mortality as the end-point.
Out of 505 patients (mean age 58.6±11.3 years) 32 died during the first 30 days (6.3%) and an additional 74 within 5 years (15.6%). PCI was successful in 95.2% (n=481). Prognostic values (c statistics) for predicting 5-year mortality equaled: 0.742 (CI 0.69-0.79) for the GRACE risk score, 0.727 (CI 0.67-0.78) for TIMI, 0.72 (CI 0.67-0.77) for Zwolle, and 0.687 (CI 0.63-0.74) for CADILLAC. In a univariate analysis all the scores were associated with the 5-year outcome.
GRACE, TIMI, and Zwolle risk scores predicted well 5-year all-cause mortality in patients with STEMI treated with pPCI. Our data show that the usefulness of initial bedside risk assessment can be further extended for long-term follow-up.
GRACE、TIMI、Zwolle 和 CADILLAC 风险评分旨在预测急性冠状动脉综合征后的短期预后。我们的研究目的是检验这些评分在经皮冠状动脉介入治疗(pPCI)治疗的 ST 段抬高型心肌梗死(STEMI)患者“真实生活”人群中预测 5 年生存率的效用。
我们的注册研究包括接受 pPCI 治疗的连续 STEMI 患者。以全因死亡率为终点进行 5 年随访。
在 505 例(平均年龄 58.6±11.3 岁)患者中,30 天内有 32 例(6.3%)死亡,5 年内另外有 74 例(15.6%)死亡。95.2%(n=481)的患者接受了成功的 PCI。预测 5 年死亡率的预后价值(c 统计量)分别为:GRACE 风险评分 0.742(95%CI 0.69-0.79)、TIMI 评分 0.727(95%CI 0.67-0.78)、Zwolle 评分 0.72(95%CI 0.67-0.77)和 CADILLAC 评分 0.687(95%CI 0.63-0.74)。单因素分析显示所有评分均与 5 年预后相关。
GRACE、TIMI 和 Zwolle 风险评分能较好地预测接受 pPCI 治疗的 STEMI 患者 5 年全因死亡率。我们的数据表明,初始床边风险评估的有用性可进一步扩展到长期随访。